Two Sigma Investments LP Acquires 63,246 Shares of Certara, Inc. (NASDAQ:CERT)

Two Sigma Investments LP lifted its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 20.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 377,524 shares of the company's stock after buying an additional 63,246 shares during the quarter. Two Sigma Investments LP owned about 0.23% of Certara worth $4,021,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of CERT. Blue Trust Inc. increased its position in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after buying an additional 822 shares during the period. KBC Group NV increased its position in shares of Certara by 64.1% during the fourth quarter. KBC Group NV now owns 7,998 shares of the company's stock worth $85,000 after buying an additional 3,125 shares during the period. Choreo LLC increased its position in shares of Certara by 25.0% during the fourth quarter. Choreo LLC now owns 50,582 shares of the company's stock worth $533,000 after buying an additional 10,118 shares during the period. Moloney Securities Asset Management LLC acquired a new stake in shares of Certara during the fourth quarter worth $128,000. Finally, Summit Trail Advisors LLC acquired a new stake in shares of Certara during the fourth quarter worth $138,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CERT shares. Stephens reissued an "overweight" rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. William Blair reissued a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Robert W. Baird increased their target price on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Finally, JMP Securities reissued a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Certara currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Stock Down 3.2%

Shares of Certara stock traded down $0.36 during trading hours on Monday, reaching $11.00. The company's stock had a trading volume of 1,538,692 shares, compared to its average volume of 1,343,115. Certara, Inc. has a one year low of $8.64 and a one year high of $17.76. The company has a market capitalization of $1.78 billion, a P/E ratio of -55.00, a P/E/G ratio of 9.29 and a beta of 1.57. The stock's fifty day simple moving average is $11.88 and its two-hundred day simple moving average is $11.81. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. During the same period last year, the firm earned $0.10 earnings per share. The business's quarterly revenue was up 9.7% compared to the same quarter last year. On average, research analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.